Paediatric Environmental Health Speciality Unit, University Hospital Virgen of Arrixaca, Murcia, Spain.
J Cyst Fibros. 2012 Jan;11(1):34-9. doi: 10.1016/j.jcf.2011.09.005. Epub 2011 Oct 13.
There have been several studies assessing the epidemiology and effects of tobacco smoke in the cystic fibrosis (CF) population, but few address the efforts of smoking cessation interventions. Our objective is to present one tobacco prevention and cessation programme targeting patients with CF in the Mediterranean region of Murcia (Spain).
All registered patients in the Regional CF unit (n=105) in 2008 were included in a cross-sectional and prospective uncontrolled study of tobacco use and exposure in CF patients using a baseline and 1-year follow-up. Target population includes both patients and other family members living at home. The study included an initial telephone questionnaire, measurement of lung function, urinary cotinine levels, and several telephone counselling calls and/or personalised smoking cessation services.
Of the 97 contacted patients, 59.8% (n=58) were exposed to environmental tobacco smoke (ETS), 12.4% (n=12) had smoked at one time, and 14.3% (n=8) of patients over the age of 15 actively smoked. The mean age was 31.13 (range: 19-45). Of the non-smokers (n=89), 56.2% reported ETS and 26.9% live with at least one smoker at home. 49.2% had urinary cotinine levels >10 ng/ml. The correlation found between patients' cotinine levels and their reported tobacco exposure was (0.77, p<0.0001). Active smoking by mothers during pregnancy was associated with significantly lower lung function in young CF patients (-0.385, p=0.04). At the 1-year follow-up, 13 individuals made attempts to stop smoking, 6 of which are now ex-smokers (12.5% of all smokers).
Smoking during pregnancy adversely affects lung function in individuals with CF. Tobacco prevention and cessation programmes are an effective and vital component for CF disease management. The trained professionals in prevention and smoking cessation services could provide patients with adequate follow-up, integrating an environmental health approach into CF patients' healthcare.
已有多项研究评估了囊性纤维化(CF)人群中烟草烟雾的流行病学和影响,但很少有研究涉及戒烟干预措施。我们的目的是介绍一个针对地中海穆尔西亚地区 CF 患者的烟草预防和戒烟计划。
2008 年,在区域 CF 单位登记的所有患者(n=105)均纳入了一项针对 CF 患者烟草使用和暴露情况的横断面和前瞻性非对照研究,采用基线和 1 年随访。目标人群包括在家中居住的患者和其他家庭成员。该研究包括初始电话问卷调查、肺功能测量、尿可替宁水平以及多次电话咨询电话和/或个性化戒烟服务。
在 97 名联系的患者中,59.8%(n=58)接触环境烟草烟雾(ETS),12.4%(n=12)曾经吸烟,14.3%(n=8)年龄在 15 岁以上的患者主动吸烟。平均年龄为 31.13 岁(范围:19-45 岁)。在不吸烟者(n=89)中,56.2%报告接触 ETS,26.9%与至少一名在家吸烟者同住。49.2%的尿可替宁水平>10ng/ml。患者可替宁水平与其报告的烟草暴露之间存在相关性(0.77,p<0.0001)。母亲在怀孕期间吸烟与 CF 年轻患者的肺功能显著下降有关(-0.385,p=0.04)。在 1 年随访时,13 人尝试戒烟,其中 6 人现已戒烟(所有吸烟者的 12.5%)。
怀孕期间吸烟会对 CF 患者的肺功能产生不利影响。烟草预防和戒烟计划是 CF 疾病管理的有效和重要组成部分。经过培训的预防和戒烟服务专业人员可以为患者提供充分的随访,将环境卫生方法纳入 CF 患者的医疗保健中。